MEK162 is an investigational drug.
There have been 71 clinical trials for MEK162.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 12th 2013.
The most common disease conditions in clinical trials are Melanoma, Neoplasms, and Carcinoma. The leading clinical trial sponsors are Array BioPharma, National Cancer Institute (NCI), and Pfizer.